Postmus P E, Mulder N H, Grampel J C, Meyers W H, Berendsen H H
Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.
Eur J Cancer Clin Oncol. 1987 Aug;23(8):1207-8. doi: 10.1016/0277-5379(87)90156-8.
Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.
反式-N3P3Az2(NHMe)4（AZP），一种氮丙啶基取代的环磷腈，在一项非小细胞肺癌的II期研究中进行了评估，剂量为每3周静脉推注0.33 mg/m²。未观察到肿瘤反应。注意到其累积骨髓毒性与其他环磷腈相当。AZP对非小细胞肺癌的治疗无效。
